Title II of DQSA, the Drug Supply Chain and Security Act, establishes requirements that allow pharmaceutical drug products to be traced and tracked as they move through the supply chain. The requirements of the DSCSA include the implementation and assignment of unique device identifiers, individual codes that will enable tracking of individual drugs and products.
Such requirements are being phased in over the next seven years. The Pew Initiatives Health Safety Project has released a timeline outlining key implementation dates for each of the sectors affected by DSCSA: manufacturers, repackagers, wholesale distributors and dispensers.
The timeline presents each requirement as it relates to each sector as well as how the DSCSA will affect relationships between sectors.
To view the timeline, click here.
More Articles on DQSA:
HSCA Files Comments on DSCSA With FDA
GS1 Healthcare US Releases UDI Implementation Guide
FDA Accredits GS1 as Issuing Agency for Unique Device Identifiers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.